Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. - Wikidata - wikimedia - TriplyDB

Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients.

Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients.

http://www.wikidata.org/entity/Q35983529

about

Management of hyperphosphataemia in chronic kidney disease: summary of National Institute for Health and Clinical Excellence (NICE) guideline Klotho, phosphate and inflammation/ageing in chronic kidney disease Vascular calcification: When should we interfere in chronic kidney disease patients and how?Stop chronic kidney disease progression: Time is approaching Plasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a Cross-Sectional Observational Study Phosphate binders in chronic kidney disease: a systematic review of recent data.Associations between the duration of dialysis, endotoxemia, monocyte chemoattractant protein-1, and the effects of a short-dwell exchange in patients requiring continuous ambulatory peritoneal dialysis.Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.Persistent immune activation in chronic HIV infection: do any interventions work?Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review The gut microbiome, kidney disease, and targeted interventions.Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection.Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.Pathophysiology and management of cardiovascular disease in patients with HIV Serious Non-AIDS events: Immunopathogenesis and interventional strategies.Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.Hyperphosphataemia: treatment options.Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials.Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection Intestinal Barrier Disturbances in Haemodialysis Patients: Mechanisms, Consequences, and Therapeutic Options.The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.The gut-kidney axis in chronic renal failure: A new potential target for therapy.Strategies to limit immune-activation in HIV patients.Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study.FGF23 and inflammation Gastrointestinal complications induced by sevelamer crystals.Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia Endotoxin binding by sevelamer: potential impact on nutritional status.Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis.Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial.Clinical factors associated with serum copper levels and potential effect of sevelamer in hemodialysis patients.Phosphate control in reducing FGF23 levels in hemodialysis patients

P2860

Q26866391-B6C3667E-9BBF-4DB4-BF88-E2E779F5799F Q27013965-D18E6D22-6BE0-470B-AECF-5A7C2D8DBA08 Q28071582-2F1C4019-72D7-4CE5-9961-8A94D3187C51 Q28078020-83123A7C-F6C6-4525-8A05-DF53EB214900 Q28535870-DB431E38-9A95-48E7-9905-DCFAE35CC722 Q31039292-B2C634EF-3F86-45E4-A72C-92DC96413F21 Q34294329-D787CF24-2FC7-416D-8078-A32AC6FD1BDC Q34430215-C8CBBC82-19FD-4360-B054-D3FE259664E8 Q34505136-F709A04F-7AD8-4834-A240-321A8A428B75 Q34851102-8BAD2F08-BDEB-4E41-AEC7-735F4155C5F0 Q35019709-506286B6-FF6E-47C4-A50C-A1814763AA88 Q35042986-5C96EDE1-CBD7-40F5-BB9E-906898192081 Q36330954-8ED233F8-C3EC-4303-8367-220955E44DEC Q36443804-819FCFDC-319C-4FB7-AD52-96F09B47A805 Q37038775-B36C948C-7927-4643-A956-40808F0E28C9 Q37418140-4B94D7EA-ACBD-4FA6-8DA3-8E7C35AFBF7C Q38092144-DEB6D31E-F1BC-4ACA-A950-75EDE0732E80 Q38102603-99F7CAAA-3AFF-44F9-8062-5C54CA31B2CF Q38210438-2F1F4242-FB41-4A43-A63F-F8E7EA1004F2 Q38229088-73AC888F-6DC5-4068-8ECE-AE599BF241C5 Q38749963-A01D2109-053C-44B1-9F3E-B384B488654D Q38757951-87802F0E-5DA5-4EC5-9974-782E9B58A750 Q38819231-C598954C-F403-49AF-989D-5196CBC63FD3 Q38955879-F4841AFE-68B2-4343-9639-DACDDE5D83BB Q38985926-CCE092E1-2983-45A4-8252-E7A500190679 Q39430387-CA2E5315-2D68-45A8-8DB9-53740E7DC9CB Q40805494-51BDEE96-7F49-4F80-95F4-9242B3865CE9 Q41510628-DA7D3764-E68C-4E89-867B-E03434F2B5B8 Q42142326-6CCFEDA5-C37A-474F-BD36-46E5BF216C86 Q42718522-60D231B4-A030-402F-868A-51605E862C6B Q44853372-0590910C-5D14-45BD-9482-273D6652F70E Q49846193-DC7AE2D4-9171-4BE3-81E1-A9009F79C10D Q51332971-62EC03D9-BED5-42F6-AD76-D72F94475268 Q58797979-B39D17DE-28DC-436F-8A7C-0B990F609BD2

P2860

Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients.

http://www.wikidata.org/entity/Q35983529

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Effect of phosphate binders on ...... vels in hemodialysis patients.

@ast

Effect of phosphate binders on ...... vels in hemodialysis patients.

@en

type

label

Effect of phosphate binders on ...... vels in hemodialysis patients.

@ast

Effect of phosphate binders on ...... vels in hemodialysis patients.

@en

prefLabel

Effect of phosphate binders on ...... vels in hemodialysis patients.

@ast

Effect of phosphate binders on ...... vels in hemodialysis patients.

@en

P1433

Q35983529-0969499B-BACB-4B87-9D2F-DCA502048BC6

P1476

Q35983529-6F9648F6-8C11-413D-8A4E-A41F63BC6681

P2093

Q35983529-54CAF34B-9B7F-48CE-9662-2755EBCC2AD8

Q35983529-7DEBCC81-1260-4E91-B432-93A901EF569F

Q35983529-90F873CC-3559-4D13-B8A7-99EB7F47F2A4

Q35983529-A2303852-60D6-46C2-955C-1BAE30CF4182

Q35983529-D25D9985-5E7F-4BA7-8CFF-EA1C072DB1AD

Q35983529-E7D07CBC-520F-4A2E-A21B-AC6BB79301A4

P2860

Q35983529-07DC60FE-EF92-49E7-AC02-822231A7E678

Q35983529-0DC61142-F0A2-44D2-B619-7974428A2BDB

Q35983529-12C1F20C-96E5-4ADF-B4ED-87AFDD300CBE

Q35983529-18D25C86-BFCC-43AC-B51A-C3AF4897E79B

Q35983529-1F6A37ED-9C4C-40A6-B782-1CE86E912F33

Q35983529-2F1DE5CB-EC21-4596-84CE-26BE4902D243

Q35983529-3747800A-1BE4-4506-BAB1-D3E2F3B35F03

Q35983529-41E0E19F-E530-4438-9EA5-70D4682119D4

Q35983529-52EAC2F6-968C-4177-A1BA-FFA05A70E562

Q35983529-5CA9841C-BEF1-40F5-95F0-6A1FF7FDA4E2

P304

Q35983529-6962FE80-0915-4EEC-9DE8-0E348A821D83

P31

Q35983529-10988E3A-8810-45CC-A9FB-2A376F5C0AE5

P356

Q35983529-20CD369F-B4DC-4980-8D04-10CC4BF40C41

P433

Q35983529-8B3CC8BA-352C-49A2-B9D9-47197AE6D79E

P478

Q35983529-FF7DE15B-FADE-4A51-8358-B9940F7BDD0E

P577

Q35983529-0BAD9810-941E-40BA-AF59-DBE22A708090

P5875

Q35983529-15C6EAE4-D340-459D-A82C-2EDBDD30D72F

P698

Q35983529-36B51372-4B42-49DE-8D21-2C95BFDF7407

P921

Q35983529-FBFA66C6-170E-4E1B-AE4A-DC316E1A8671

P932

Q35983529-EA5A6E84-C9A6-423D-9AD0-9CBCAF0CBCEE

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Effect of phosphate binders on ...... vels in hemodialysis patients.

@en

P2093

Carmen Mora-Fernández

http://www.w3.org/2001/XMLSchema#string

Javier Donate-Correa

http://www.w3.org/2001/XMLSchema#string

Javier García-Pérez

http://www.w3.org/2001/XMLSchema#string

Juan F Navarro-González

http://www.w3.org/2001/XMLSchema#string

Mercedes Muros de Fuentes

http://www.w3.org/2001/XMLSchema#string

Violeta Cazaña-Pérez

http://www.w3.org/2001/XMLSchema#string

P2860

IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly.

Initial responses to endotoxins and Gram-negative bacteria.

The effects of hemodialysis and peritoneal dialysis on serum homocysteine and C-reactive protein levels

Inflammation in end-stage renal disease: the hidden enemy.

Inflammatory syndrome in patients on hemodialysis.

Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients.

Pleiotropic effects of the non-calcium phosphate binder sevelamer.

Association of soluble endotoxin receptor CD14 and mortality among patients undergoing hemodialysis.

Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study.

Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients.

P304

2272-2279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.01650211

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51517124

http://www.w3.org/2001/XMLSchema#string

P698

21784820

http://www.w3.org/2001/XMLSchema#string

P921

P932

3359006

http://www.w3.org/2001/XMLSchema#string